Abstract 3206
Background
Erdafitinib (Erda), a pan-FGFR tyrosine kinase inhibitor, recently received accelerated approval by US FDA for treatment of post-platinum advanced UC pts with certain FGFR3 or 2 alterations. Erda induces dose dependent hyperphosphatemia via inhibition of PO4 excretion.
Methods
Ph1 data and PK/PD modeling identified a serum PO4 level of ≥ 5.5 mg/dL as a PD target with acceptable tolerability. In a ph2 study (NCT02365597) pts started Erda at 8mg/day, serum PO4 was assessed every cycle, and Cycle 1 Day 14 (C1D14). Up-titration on C1D15 to 9mg/day occurred if serum PO4 was < 5.5 mg/dL and pts had no significant investigator assessed toxicity. Objective response rate (ORR) and disease control rate (DCR) were assessed by logistic regression analysis; progression free survival (PFS), and overall survival (OS) were calculated by Cox regression methods.
Results
99 patients started 8 mg Erda and 41% were up-titrated to 9 mg based on C1D14 PO4 levels. The ORR and DCR were higher (42.7% and 85.3%) when maximum PO4 levels were >5.5 mg/dL as compared to below (34.8% and 65.2%, respectively). Median OS and PFS were prolonged with levels >5.5 mg/dL as compared to below with hazard ratio of 0.35 (median not reached vs 6.7 months) and 0.68 (5.6 vs 3.8 months), respectively. Among patients that could not be up-titrated due to concurrent toxicities, ORR was 27.3% (n = 22; 95% CI- 8.7%, 45.9%) as compared to 48.8% (n = 41; 95% CI-33.5%, 64.1%) for patients who were up-titrated. Logistic regression analysis (ORR, DCR), and Cox regression (PFS, OS) showed that maximum phosphate levels positively correlated with ORR, DCR, PFS, and OS (Table).Table:
932P ORR, DCR, PFS, OS and maximum on-treatment serum PO4*
ORR | DCR | PFS | OS | |
---|---|---|---|---|
ORb, (95% CI), p-valuec | ORb, (95% CI), p-valuec | HR, (95% CI), p-valuee | HR, (95% CI), p-valuee | |
Prognostic variablea | ||||
Maximum PO4: per 1 mg/dL increase | 1.25, (0.86, 1.81), 0.247 | 2.31, (1.31, 4.08), 0.004 | 0.78, (0.63, 0.96), 0.021 | 0.58, (0.43, 0.80), 0.001 |
Simulated outcomes via PK/PD modeling of up-titrating from 8 mg to 9 mg QDf | 1.10 (0.93, 1.29), - | 1.43 (1.12, 1.83), - | 0.90 (0.82, 0.98), - | 0.79 (0.70, 0.91), - |
The median time to maximum = 1.3m. Note: a. variable in model. b. odds ratio c. Pearson’s chi-square p-value e. Pearson’s chi-square p-value f. derived from first row using OR0.43 and HR0.43, based on PKPD simulations predicting average 0.43 mg/dL increase in maximum PO4 from 8 to 9 mg at steady state.
Conclusions
Hyperphosphatemia in Erda treated pts is associated with improved outcomes, supporting optimization of Erda dosing via uptitration based on serum PO4.
Clinical trial identification
NCT02365597, February 19, 2015.
Editorial acknowledgement
Himabindu Gutha (SIRO Clinpharm Pvt. Ltd.) writing assistance, Dr. Harry Ma (Janssen Research & Development, LLC) additional editorial support.
Legal entity responsible for the study
Janssen Research & Development.
Funding
Janssen Research & Development.
Disclosure
S.T. Tagawa: Advisory / Consultancy: Medivation, Astellas Pharma, Dendreon, Janssen, Bayer, Genentech, Endocyte, Immunomedics, Karyopharm Therapeutics, AbbVie, Tolmar, QED, Amgen, Sanofi; Research grant / Funding (institution): Lily, Sanofi, Janssen, Astellas Pharma, Progenics, Millennium, Amgen, Bristol-Myers Squibb, Dendreon, Rexahn Pharmaceuticals, Bayer, Genentech, Newlink Genetics, Inovio Pharmaceuticals, AstraZeneca, Immunomedics, Novartis, AVEO, Boehringer Ingelheim, Merc; Travel / Accommodation / Expenses: Sanofi, Immunomedics, Amgen. A.O. Siefker-Radtke: Advisory / Consultancy: Janssen, Threshold Pharmaceuticals, Merck, National Comprehensive Cancer Network, Eisai, Genentech, Vertex, AstraZeneca, EMD Serono, Bristol-Myers Squibb; Speaker Bureau / Expert testimony: Genentech; Research grant / Funding (self): National Institutes of Health, Genentech, Janssen Pharmaceuticals, Millennium, Michael and Sherry Sutton Fund for Urothelial Cancer. A. Dosne: Full / Part-time employment: Janssen Research and Development. B. Zhong: Full / Part-time employment: Janssen Research and Development. W.S. Shalaby: Full / Part-time employment: Janssen Research and Development. A. O’Hagan: Full / Part-time employment: Janssen Research and Development. K. Qi: Stockholder / Stock options, Full / Parttime employment: Janssen Research and Development. P. De Porre: Full / Part-time employment: Janssen Research and Development. P. Mahadevia: Full / Part-time employment: Janssen Research and Development. Y. Loriot: Advisory / Consultancy: Astellas Oncology; AstraZeneca; Ipsen; Janssen; MSD; Roche; Sanofi; Research grant / Funding (self): Sanofi (Inst); Travel / Accommodation / Expenses: AstraZeneca; MSD; Roche. All other authors have declared no conflicts of interest.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract